Results 181 to 190 of about 281,748 (215)

JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications

Beatríz Bellosillo, Michael Doubek, Ciprian Tomuleasa, Martin Grießhammer, Monia Marchetti, Tomasz Sacha, Heinz Gisslinger   +6 more
openalex   +1 more source

Cardiac hypertrophy in polycythemia vera: A case report and review of literature. [PDF]

World J Cardiol
Ma BS, Zhai SH, Chen WW, Zhao QN.
europepmc   +1 more source

Regression of Left Ventricular Hypertrophy After Polycythemia Vera Treatment With Incidental Finding of Unicuspid Aortic Valve. [PDF]

JACC Case Rep
Li A, Kaphle R, Zanotti G, Chaudhry SP.
europepmc   +1 more source

Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea. [PDF]

Leukemia
Palandri F, Breccia M, Elli EM, Latagliata R, Benevolo G, Morsia E, Tiribelli M, Cavazzini F, D'Addio A, Tieghi A, Farina M, Cavalca F, Dedola A, Heidel FH, Palumbo GA, Rossi E, Branzanti F, De Stefano V.   +17 more
europepmc   +1 more source

Precision Dosing in Presence of Multiobjective Therapies by Integrating Reinforcement Learning and PK-PD Models: Application to Givinostat Treatment of Polycythemia Vera. [PDF]

CPT Pharmacometrics Syst Pharmacol
De Carlo A, Tosca EM, Magni P.
europepmc   +1 more source

Psychiatric Manifestations in Polycythemia Vera: A Case of Refractory Delirium and Psychosis Responding to Hematological Treatment [PDF]

Turk J Haematol
Yıldırım YE, Erözeren HI, Gültürk E, Çağlar Tanrıverdi N, Balaban ÖD.   +4 more
europepmc   +1 more source

Reversibility of acrocyanosis and improvement of capillaroscopic pattern in a patient with polycythemia vera treated with ruxolitinib: a case report. [PDF]

Blood Res
Nigro A.
europepmc   +1 more source

Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab. [PDF]

Dermatol Pract Concept
Zafiriou E, Karampinis E, Papadopoulos V, Stefani G, Kotsakis A, Vassilopoulos G.   +5 more
europepmc   +1 more source

Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system

E. Walter, Francesca Torelli, Tiziano Barbui   +2 more
openalex   +1 more source

Correction: Efficacy and safety of pegylated interferon in the treatment of JAK2^V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study. [PDF]

Front Oncol
Chang L, Li WX, Cai H, Li J, Duan MH.
europepmc   +1 more source